



ASX Release

2 December 2025

ASX code: PIQ

Proteomics International

LABORATORIES LTD

2 December 2025

Attn: Melissa Kostopoulos
ASX Compliance Pty Limited
Via Email: melissa.kostopoulos@asx.com.au

Dear Melissa

PROTEOMICS INTERNATIONAL LABORATORIES – RESPONSE TO ASX PRICE QUERY

We refer to your letter dated 2 December 2025 and respond as follows (defined terms have the same meaning given to them in your letter):

- 1. Is PIQ aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?**

The Company is not aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities.

- 2. If the answer to question 1 is “yes”.**

N/A

- 3. If the answer to question 1 is “no”, is there any other explanation that PIQ may have for the recent trading in its securities?**

Proteomics International notes that it has made several market sensitive announcements in recent weeks, including:

26 November 2025: US Medicare sets reimbursement price for next-generation PromarkerD predictive test for diabetic kidney disease. Highlights included:

- The US Centers for Medicare & Medicaid Services (CMS) have set the payment rate for the next-gen PromarkerD predictive test for diabetic kidney disease at US\$390.75
- CMS determination underpins Proteomics International's US launch strategy, broadening patient access and strengthens the Company's discussions with private payers and strategic partners
- CMS is the single largest payer for health care in the United States, with Medicare and Medicaid collectively responsible for 42 per cent of healthcare spending

24 November 2025: OxiDx oxidative stress biomarker correlates with enhanced performance in Australian Thoroughbred racehorses. Highlights included:

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Part of the PILL Group

- New performance data in Thoroughbred racehorses shows racing without oxidative stress increased performance, with 88% of top-three finishers racing without oxidative stress: horses without oxidative stress were 76% more likely to place and 49% more likely to win.
- OxiDx's patented technology detects a sensitive biomarker of systemic oxidative stress linked to muscle damage, poor recovery and increased injury risk.
- The findings mark a key milestone confirming the OxiDx test's potential to enhance performance management and improve welfare outcomes in Thoroughbred racehorses.

Also as disclosed in recent announcements, the Company has achieved a number of significant milestones including:

- Clinical certification was received for its Australian diagnostics laboratory, enabling the Company to provide pathology testing for its precision diagnostic tests.
- PromarkerD and PromarkerEso have been launched in Australia and initial sales have been achieved.

These recent ASX announcements, may have contributed to heightened investor interest. The Company confirms that it is not aware of any further information that has not already been disclosed to the market.

The Company remains focused on executing its growth strategy across its Promarker® pipeline and will continue to keep the market informed in accordance with ASX Listing Rules.

4. Please confirm that PIQ is complying with the Listing Rules and, in particular, Listing Rule 3.1.

The Company confirms that, to its best knowledge and belief, it is in compliance with ASX Listing Rules and in particular, Listing Rule 3.1.

5. Please confirm that PIQ's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of PIQ with delegated authority from the board to respond to ASX on disclosure matters.

The Company confirms that these responses to ASX's Letter have been authorised and approved by the Managing Director and Chairman under delegated authority from the Board to respond to ASX on disclosure matters.

This announcement has been authorised for release by: Dr Richard J Lipscombe, Managing Director and James Williams, Chairman.

For further information please contact:

Dirk van Dissel
 Investor Relations & Corporate Advisory
 Candour Advisory
 T: +61 408 326 367
 E: dirk@candouradvisory.com.au

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Part of the PILL Group

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Part of the PILL Group



2 December 2025

Mr Tim Luscombe
Company Secretary
Proteomics International Laboratories Ltd

By email: tim.luscombe@bio101.com

Dear Mr Luscombe

Proteomics International Laboratories Ltd ('PIQ'): Price - Query

ASX refers to the following:

- A. The change in the price of PIQ's securities from a closing price of \$0.40 on 1 December 2025 to an intraday high of \$0.55 today.
- B. The significant increase in the volume of PIQ's securities traded from 1 December 2025 to 2 December 2025.

Request for information

In light of this, ASX asks PIQ to respond separately to each of the following questions and requests for information:

1. Is PIQ aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes".
 - (a) Is PIQ relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in PIQ's securities would suggest to ASX that such information may have ceased to be confidential and therefore PIQ may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that PIQ may have for the recent trading in its securities?
4. Please confirm that PIQ is complying with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that PIQ's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of PIQ with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **3:00 PM AEDT Tuesday, 2 December 2025**. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, PIQ's obligation is to disclose the information

‘immediately’. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require PIQ to request a trading halt immediately.

Your response should be sent to me by e-mail at ListingsComplianceMelbourne@asx.com.au. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is “yes” and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in PIQ’s securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in PIQ’s securities under Listing Rule 17.3.

Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to PIQ’s obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that PIQ’s obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

Yours faithfully

ASX Compliance